"The Omics Revolution: Towards Personalised Medicine"
This satellite follows on from the previous successful meetings in this series (Proteomics Forum, Malaysia and The “Omics” Revolution: Uncovering Proteome Complexity) that were held in conjunction with the 2013 APC meeting in Penang and the 2015 meeting in Kingscliff, Australia, respectively. The theme for this meeting we be "The Omics Revolution: Towards Personalised Medicine". This will cover recent advances in Omics technologies, including hyphenated targeted and DIA strategies that are assisting in the development of Personalised Medicine. The program committee is putting together an exciting list of National and International speakers that will address emerging MS and other omics technologies, the HUPO search for “missing proteins”, the microbiome, big data analysis and novel omics applications including translational proteomics and diagnostics.
HUPO Australia /New Zealand
Chromosome 7 Initiative
UNIVERSITY OF MELBOURNE
Berin Boughton received his PhD (Chemistry) from the University of Melbourne in 2010 in the area of drug development, design, inhibition and kinetics. Dr Boughton joined Metabolomics Australia, an NCRIS funded core facility in 2009 in the lab of Prof. Ute Roessner, where his scientific research has focussed on bioanalytical mass spectrometry with particular emphasis upon metabolomics and development of spatial metabolomics methods, aiming to measure many metabolites within a biological system both comprehensively and quantitatively, including in a spatial manner. Since 2013 Dr Boughton has led the implementation and development of ultra-high resolution matrix assisted laser desorption ionisation mass spectrometry imaging (MALDI-MSI) at the University of Melbourne, developing novel matrices and applying this technology to numerous systems, including the mapping of plant secondary metabolites and defense molecules, plant responses to abiotic stress, host-parasite interactions and drug distribution studies.
Brian was born in Cape Town, South Africa. He received his B. Sc. (1969) and B. Sc. (Hons) (1970) from the University of Cape Town and D.Phil. (1976) in experimental nuclear physics from Oxford University. He is currently Camille and Henry Dreyfus Professor at Rockefeller University in New York, where he is Head of the Laboratory for Mass Spectrometry and Gaseous Ion Chemistry. He also directs the NIH-funded National Resource for the Mass Spectrometric Analysis of Biological Macromolecules. Professor Chait has received several awards for his research in developing instrumentation and methods for characterizing proteins, including the 2000 Bijvoet Medal, the 2002 ACS Field & Franklin Award for Outstanding Achievement in Mass Spectrometry, the 2007 HUPO 2007 Distinguished Discovery Award In Proteomics, the 2012 Per Edman Award, and the 2015 ASMS Award for a Distinguished Contribution in Mass Spectrometry. He has co-authored 391 publications (46,500 citations) and has been awarded 30 US patents.
Roger was awarded his PhD from the University of Liverpool, UK before taking up positions as a postdoctoral fellow at the Imperial Cancer Research Fund, London, UK followed by New York University Medical Centre, New York, USA. He established the Signal Transduction Group at the Garvan Institute of Medical Research in 1993, and moved to Monash University in 2013, where he is Professor of Signalling Network Biology, Head of the Department of Biochemistry and Molecular Biology and Head of the Biomedicine Discovery Institute Cancer Program. Roger’s research focus is tyrosine kinase signalling mechanisms and their deregulation in cancer. Recently, his laboratory's research strategy has changed from a largely candidate-based approach, based on mechanistic and functional analysis of individual signalling proteins, to one which includes global interrogation of signalling networks by mass spectrometry-based phosphoproteomic profiling of cancer subtypes and global interrogation of the human kinome, combined with bioinformatics and functional genomics. This cutting edge proteomics work has led to the characterization of the signalling network characteristics of triple negative breast cancer cells, identification of mechanisms of docetaxel resistance in castrate-resistant prostate cancer, definition of novel subtypes of pancreatic cancer, and mapping of global kinome responses to specific oncogenes. Overall this strategy is identifying novel therapeutic targets and biomarkers for particular poor prognosis human cancers.
Christie Hunter is the Director of Omics Applications at SCIEX. Christie and her team are focused on developing and testing innovative MS workflows for the quantitative analysis of proteins and peptides, and work collaboratively with the instrument, chemistry and software research groups. Most recently, Christie has focused on the application of SCIEX’s Industrialized Proteomics solutions, including SWATH™ Acquisition, Microflow LC separations, automated protein digestion methods and OneOmics™ cloud-computing to the analysis of very large sample cohorts, as will be required for precision medicine. Christie received her Ph.D. in protein biochemistry from the University of British Columbia (Canada) in 1997 and did her post-doctoral research at a small biotechnology company, Gryphon Sciences, from 1997 to 2000.
CHILDRENS RESEARCH INSTITUTE
Vera began her research career by establishing the Haematology Research Laboratory at the Murdoch Childrens Research Institute, Melbourne in mid-2001. She has since then developed a highly productive, internationally competitive research laboratory in the field of paediatric haemostasis. Her research focuses on Developmental Haemostasis, the concept that describes age-specific differences in the haemostatic system and the implications of those differences in anticoagulation treatment in children. Following her introduction to the world of Proteomics in 2008, her interest in this methodological approach has risen dramatically and she is committed to promoting the use of proteomics in translational research. She has previously served as a member of the Australasian Proteomics Society board of management. A/Prof Ignjatovic co-founded the Paediatric Proteomics (PediOme) initiative through HUPO and recently coined the term Developmental Proteomics. She is currently the proteomics consultant on a number of projects ranging from investigations of lung injury in prematurity to mild traumatic brain injury and vascular malformations in children.
Patricia received her PhD in Immunology from the University of Melbourne in 2014 where she undertook studies centred on the Human leukocyte antigen (HLA)-associated adverse drug reaction abacavir hypersensitivity syndrome. These studies provided a new paradigm for presentation of drugs by HLA molecules (Nature 2012) and were recognised with a Commendation for the Victorian Premier's Awards for Health and Medical Research in 2013. On completion of her PhD, Patricia moved to the laboratory of Prof Tony Purcell at Monash University where, as an NH&MRC Peter Doherty Early Career Research Fellow, she has continued to investigate HLA-associated disease, utilising a combination of mass spectrometry, structural biology and functional immunology. Her current research focuses on the interplay between genetic factors (HLA polymorphisms, antigen processing machinery) and environmental factors (therapeutic drugs, infection) that shapes peptide presentation by the HLA molecules and impacts the susceptibility/resistance of individuals to hypersensitivity, infectious and autoimmune disease.
UNIVERSITY OF MELBOURNE
Neil gained his undergraduate dental degree (BDS) at University of Sydney in 1974, specialist degree in Periodontics (MDSc) at the University of Queensland in 1982, and his PhD at the University of Sydney in 2000. He has published over 60 papers in peer reviewed journals many based upon the metabolomics of pain syndromes including MECFS. He has been an editor of an international journal, on several editorial boards and has been involved in research at several universities in Australia (Melbourne University and Victoria University) and abroad in both dental and medical research fields (Stanford University CA USA, University of Nevada NV USA, Nova South-Eastern University, Fl USA). He is an Honorary Senior Fellow at the University of Melbourne in the Faculty of Medicine, Dentistry and Health Sciences. He is a supervisor of research projects for postgrad students at both Melbourne and Victoria University where he is an Adjunct Professor. He is a consultant to a NATA accredited pathology company and has an academic interest in the science of metabolomics, microbiology, genetics, inflammatory mediated disease and chronic pain disorders.
Chris is a Professor and Canada Research Chair in Protease Proteomics and Systems Biology, U.B.C. Vancouver. With 23 Nature Review, Science, and Nature/Cell/Science-sister journal papers (h-index 67), he is a pioneer of degradomics, a term he coined. He completed his Ph.D. at the University of Toronto; and post-doctoral work with Dr. Michael Smith, Nobel Laureate. In 1997/1998 was a Visiting Senior Scientist at British Biotech, Oxford and in 2004/2008 a Visiting Senior Scientist at Novartis, Basel, and is now an Honorary Professor, Albert-Ludwigs Universität Freiburg. Dr. Overall was 2002 CIHR Scientist of the Year, the UBC Killam Senior Researcher Award 2005, and was Chair of the 2003 MMP and the 2010 Protease Gordon Research Conferences. He was recognized by the IPS with the 2011 Lifetime Achievement Award; by the Matrix Biology Society of Australia and New Zealand with the 2012 Barry Preston Award; and in 2014 by the Tony Pawson Canadian National Proteomics Network Award for Outstanding Contribution and Leadership to the Canadian Proteomics Community. He is also an elected member of HUPO Executive Committee, the Chromosome Centric Human Proteome Project (C-HPP) Executive Committee, and is an Associate Editor of the Journal of Proteomics Research.
Professor Phil Robinson is Head of the Cell Signalling Unit at CMRI since 1996 and Professor of Medicine and Chemistry at the Universities of Sydney and Newcastle. He is a Senior Principle Research Fellow (SPRF) of the Australian NHMRC (National Health and Medical Research Council) since 1997. He obtained a PhD in medical biochemistry from The University of Newcastle (Australia) and has postdoctoral training at the NIH in Bethesda, followed by the Pharma company Merrell Dow in Cincinnati. He is best known for his research on molecular mechanisms of endocytosis, drug discovery, protein function, and phosphoproteomics. He applies these to neuroscience and cancer, being among the top 4 drug target groups for the worlds’ 2,800 clinically approved drugs. His work has been defining the proteins and kinases involved in molecular mechanisms and regulation of endocytosis in neurons and cancer, with focus on dynamin. One outcome has been his development a comprehensive pharmacology of endocytosis, leading to new drug options for cancer, infectious disease and epilepsy. He is recognised for his leadership in functional proteomic approaches to cell signalling. He co-leads ProCan, the new ‘ACRF International Centre for the Proteome of Human Cancer', launched Q3 2016, which is largest international cancer proteome-mapping project undertaken.
UNIVERSITY OF SYDNEY
Sunday 15 October
Session A: Omics Applications
Session B: Clinical Applications
Session C: Cancer Proteomics
Joint Session with APC: Emerging Trends in Proteomics
Opening Session 12th APC
This symposium is at no charge for all delegates registered to attend the 12th Australian Peptide Conference. For those wishing to only attend the Proteomics Forum there will be a one day registration fee of AUD$175 (students AUD$100). Full details on abstract submission can be found here. Abstracts can be submitted for both oral and poster presentations. Please note that posters will be displayed during the poster sessions of the main meeting.
Melanie White is a medical biochemist at The University of Sydney, whose research investigates heart disease and type 2 diabetes with the use of proteomic technologies. She graduated with a PhD in 2006 from the laboratory of Professor Richmond Jeremy, before receiving an NHMRC CJ Martin Fellowship. This allowed Dr White to undertake research in the laboratory of Professor Jennifer Van Eyk at Johns Hopkins School of Medicine (USA). Here she investigated the role of the mitochondria in myocardial protection. After her return to the University of Sydney and the laboratory of Professor Stuart Cordwell, she was awarded an inaugural DECRA fellowship to develop enrichment methods for modified peptides. She is a scientific editor with the Journal of Molecular and Cellular Cardiology and has been awarded the Australasian Proteomics Society Young Investigator Award. Her group works towards using these enrichment methods to analyze post-translational modifications on peptides to understand their role in heart disease and type 2 diabetes.